- Role of pirfenidon in idiopathic pulmonary fibrosis treatment2018 | First Faculty of Medicine
- Pirfenidone in the treatment of idiopathic pulmonary fibrosis +12015 | First Faculty of Medicine
- Pharmacotherapy of idiopathic pulmonary fibrosis - current treatment and future concepts2019 | First Faculty of Medicine
- Position of pharmacotherapy in the treatment of idiopathic pulmonary fibrosis2018 | First Faculty of Medicine
- Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry2019 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Second Faculty of Medicine
- Současné možnosti léčby idiopatické plicní fibrózy - výhledy2020 | Second Faculty of Medicine
- Current pharmacotherapy of idiopathic pulmonary fibrosis2016 | First Faculty of Medicine
- Idiopathic pulmonary fibrosis - from therapeutic nihilism to effective pharmacotherapy2016 | First Faculty of Medicine
- Multidisciplinary team in care of patients with interstitial lung disease2017 | Faculty of Medicine in Hradec Králové
- This should not happen to respiratory specialist - unfortunate end of IPF story in Czech Republic2015 | First Faculty of Medicine
- Treatment of idiopathic pulmonary fibrosis in the Czech republic in 2015 +12015 | First Faculty of Medicine
- Interstitial lung disease, no more stagnant water2015 | First Faculty of Medicine
- Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone2022 | First Faculty of Medicine
- Antifibrotická léčba u idiopatické plicní fibrózy2019 | First Faculty of Medicine
- DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Second Faculty of Medicine
- News in treatment of idiopathic pulmonary fibrosis +12015 | First Faculty of Medicine
- Esbriet v léčbě idiopatické plicní fibrózy2015 | First Faculty of Medicine
- Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study2019 | First Faculty of Medicine
- Přínos antifibrotik v léčbě pacientů s non-IPF fibrotizujicími intersticiálními plicními procesy2021 | First Faculty of Medicine, Second Faculty of Medicine
- Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE2020 | First Faculty of Medicine
- Nintedanib v léčbě idiopatické plicní fibrózy2015 | First Faculty of Medicine
- Možná, pravděpodobná, nebo jistá idiopatická plicní fibróza?2016 | First Faculty of Medicine
- Jak mění antifibrotika příběhy pacientů s plicní fibrózou2022 | First Faculty of Medicine, Second Faculty of Medicine
- Biologic treatment of idiopathic pulmonary fibrosis2014 | First Faculty of Medicine
- The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Second Faculty of Medicine
- Nintedanib in the treatment of idiopathic pulmonary fibrosis2016 | First Faculty of Medicine
- Idiopathic pulmonary fibrosis - news about its diagnostics and treatment2014 | First Faculty of Medicine